AU7211091A - Creación de Inventos y Patentes con Inteligencia Artificial

AU7211091A – Novel vaccine and method therefor
– Google Patents

AU7211091A – Novel vaccine and method therefor
– Google Patents
Novel vaccine and method therefor

Info

Publication number
AU7211091A

AU7211091A
AU72110/91A
AU7211091A
AU7211091A
AU 7211091 A
AU7211091 A
AU 7211091A
AU 72110/91 A
AU72110/91 A
AU 72110/91A
AU 7211091 A
AU7211091 A
AU 7211091A
AU 7211091 A
AU7211091 A
AU 7211091A
Authority
AU
Australia
Prior art keywords
pertussis
antigen
solution
vaccine
glutaraldehyde
Prior art date
1990-02-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU72110/91A
Other versions

AU646019B2
(en

Inventor
Carine Capiau
Jean Petre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline Biologicals SA

Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1990-02-12
Filing date
1991-02-07
Publication date
1991-09-03

1991-02-07
Application filed by SmithKline Beecham Biologicals SA
filed
Critical
SmithKline Beecham Biologicals SA

1991-09-03
Publication of AU7211091A
publication
Critical
patent/AU7211091A/en

1994-02-03
Application granted
granted
Critical

1994-02-03
Publication of AU646019B2
publication
Critical
patent/AU646019B2/en

2011-02-07
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K39/00—Medicinal preparations containing antigens or antibodies

A61K39/02—Bacterial antigens

A61K39/099—Bordetella

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K39/00—Medicinal preparations containing antigens or antibodies

A61K39/385—Haptens or antigens, bound to carriers

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K39/00—Medicinal preparations containing antigens or antibodies

A61K39/02—Bacterial antigens

A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups

Abstract

A detoxified B. pertussis toxin or antigenic preparation is described, which is characterized by stability to reversion to toxicity upon storage at 4-8 DEG C and at temperatures above 23 DEG C. Also provided are methods for producing detoxified pertussis toxin and vaccines containing same.

Description

NOVEL VACCINE AND METHOD THEREFOR
Technical Field
The present invention relates generally to a process for detoxifying or toxoiding a toxic antigen from a selected pathogen in a form safe for use as a human vaccinal agent. More specifically, the invention provides a method for detoxifying pertussis toxin and using the resulting toxoid as a component in a vaccine for Bordetella pertussis.
Background of the Invention
Whooping Cough, or pertussis, is a highly infectious disease which primarily affects children. In addition to causing respiratory complications, whooping cough may result in nerve damage and high mortality, particularly in children in low socioeconomic groups and in newborn infants without maternal anti-pertussis antibodies. The etiologic agent of pertussis is the gram negative coccobacillus Bordetella pertussis. The bacteria are believed to invade the • respiratory tract and induce a toxic state which remains even after the disappearance of the bacteria.
Although world health organizations presently recommend the immunization of infants to prevent the incidence and spread of pertussis, great concern has arisen over the negative effects of various vaccine forms. The toxicity of conventional B. pertussis vaccine formulations causes side effects which vary from simple flushing to permanent neurological damage and/or death. Consequently, reduced use of conventional B. pertussis vaccines has resulted in re- explosion of the incidence of pertussis cases. The most widely used vaccine contains whole B. pertussis organisms which are inactivated after treatment at 56°C for 30

minutes. Since the bacteria are not subjected to any detoxification treatment, any toxic substance which can withstand the elevated temperature is included in the vaccine and contributes to the occurrence of side effects. Another consequence of this type of vaccine is the formation of a broad spectrum of antibodies as a response upon administration. The sera induced by such vaccines lack high specificity and high protecting potential for use as preventive or therapeutic treatments, and have no value at all as diagnostic materials.
The most important methods for detoxifying pathogens for vaccine use are heat and chemical treatment with formaldehyde or glutaraldehyde. However, variabilities in cultivation of culture supernatant of B. pertussis allow the final composition of the microorganism to vary, and the deactivating agents, glutaraldehyde or formaldehyde, occasionally lead to aggregated materials subject to conversion to active toxic substances upon storage.
For example, U. S. Patent No. 3,983,229 by Relyveld relates to a process for preparing vaccines by contacting a virus with glutaraldehyde at a concentration between 0.00131 M to 0.0526 M for between one and three hours. This process occurs at temperatures between 35° and 40°C and the reaction may be stopped by the addition of an agent able to block glutaraldehyde or react with glutaraldehyde in its free state. The blocking agent can be an amino acid or an inorganic salt. U. S. Patent No. 4,070,454 by Relyveld discloses another process for preparing a viral vaccine which involves inactivating the virus with glutaraldehyde at a concentration of 0.00263 M for between 1.5 hours to about 5 days. U. S. Patent No. 4,075,321 further improves this process for inactivating bacterial toxins by reacting whole bacteria with glutaraldehyde at a concentration of from about 0.00131 to 0.0526 M.

Gupta, J. Biol. Stand., 15.:159-164 (1987) compares whole cell vaccines obtained via the classical heat treatment with those obtained via Relyveld’s method of glutaraldehyde detoxification reaction. Both types of vaccine clearly lose 30 to 50% of their potency upon storage at 35°C for 30 days. Further, these preparations have important disadvantages when compared with more recently developed acellular or component vaccines, e.g., low immunogenicity and serious side effects caused by residual toxicity upon administration. These vaccines have proven to be much less protective than those prepared from virulent strains. See Wardlaw et al, J. Med. Micro. Biol., 9 :89-100 (1976).
To avoid the side effects caused by whole virus vaccines, research turned to the investigation of the toxic components of the B. pertussis bacteria for use in acellular and component vaccines. One important 13. pertussis antigen is pertussis toxin (PT) , a protein exotoxin which plays a major role in the pathogenesis of whooping cough and is believed to be the major protective antigen of B. pertussis [A. A. Weiss et al, Ann. Rev. Microbiol., 40.:661 (1986)1. PT induces various serious biopathological changes, whether present alone or as a contaminant of other antigenic factors from this organism, at such a low amount that it impedes the administration of B. pertussis cells or cell extracts as vaccine components in amounts sufficient to provide a good level of protection. Therefore, B. pertussis cells or cell extracts must be detoxified prior to their use in a vaccine preparation.
For the detoxification of PT (or of an acellular or component vaccine mixture containing PT) , three major methods have been described. In European patent application publication No. 121249A the hemagglutinin fraction, purified from a B. pertussis culture supernatant and containing PT, is detoxified with formalin in the presence of an amino

acid, and subsequently used for the formulation of a vaccine. The immunogenicity and the degree of detoxification reached are excellent, but the toxicity restores partially upon storage of the vaccine preparation at 37°C for 30 days.
Munoz, Infect. Immunol., 3_2.:243-250 (1981) applied a detoxification method analogous to the one of Relyveld to PT, but in the presence of salt. After two hours incubation at room temperature in the presence of 0.05% glutaraldehyde, subsequent addition of lysine up to 0.02M and another two hours of incubation, and final dialysis, an anatoxin with high immunogenicity was produced. This anatoxin was stable; its toxicity did not restore after 30 days storage at 37°C.
However, the degree of detoxification was lower than obtained with the formalin/amino acid method.
In European patent application publication No. 202947A carbodiimides are presented as efficient reagents for the detoxification of PT and B. pertussis fractions containing PT. However, the toxoids obtained are not stable upon 30 day storage at 37°C.
There thus remains a continuing need in the art for effective and safe vaccines against whooping cough which retain their activity and do not revert to toxicity upon storage.
Summary of the Invention
As one aspect, the present invention provides a method for the detoxification of a selected toxic antigen from a pathogenic microorganism. The method of the present invention involves the steps of partially detoxifying the

selected toxin or a composition containing the toxic antigen with glutaraldehyde, followed by reacting the partially detoxified toxin with formalin in the presence of selected amino acids. The resulting toxoid or toxoid-containing preparation is stable against reversion to toxicity under the influence of temperatures above about 23°C, i.e., room temperature.
One exemplary antigen employed to illustrate the use of this method is the B. pertussis toxin. Other toxins which may be subjected to the method of this invention include, for example, tetanus toxin or diphtheria toxin. This method can be used to inactivate the toxin, e.g., pertussis toxin (PT) , which is present as a primary component or only as a contaminant in preparations containing antigenic factors which are non- toxic alone, e.g., the other B. pertussis antigens FHA, 69K and agglutinogens. The method of this invention can reduce the toxicity associated with the presence of the selected toxin alone or in compositions of other antigenic factors of the same pathogen to suitable levels for use in vaccine formulations.
As another aspect, this invention provides detoxified pertussis toxin that is stable to reversion to toxicity at temperatures of 23°C or above. This toxoid of the invention is also characterized by a high degree of immunogenicity, as is demonstrated by the ability of the toxoid to induce neutralizing antibodies. The presence of neutralizing antibody is detected by specific assays, i.e., histamine sensitization of mice or clustering of Chinese Hamster Ovary cells. The detoxified toxins of this invention are stable enough to preserve immunogenicity for more than a month under adverse storage conditions at 37°C. These toxoids are useful starting materials for the composition of high quality B. pertussis vaccines, and may also be used for mixed vaccines, or for the preparation of hyperimmune sera.

As another aspect of the present invention, there are provided compositions of B_. pertussis antigenic factors, e.g., filamentous hemagglutinin (FHA) , the 69K factor or other B. pertussis agglutinins, which are useful for the preparation of vaccines to the organism and which contain at least trace amounts of detoxified PT toxin as above- described.
In still a further aspect, vaccines against B. pertussis infection are provided which remain stable at temperatures of up to 56°C and do not require special cold shipping and delivery conditions. The vaccines of this invention are characterized by easy maintenance and storage under less than optimal conditions. The vaccines developed using the toxoids of the present invention enable vaccination programs to be executed in isolated or poorly developed regions, where cold storage conditions normally required for the maintenance of other toxoided vaccines is unavailable and atmospheric conditions are extreme. Even in such conditions the vaccines of this invention are stable, and of high quality.
Still a further aspect of this invention is a method for preparing mono- or multifunctional vaccines incorporating an effective amount of the toxoids of the present invention. Other aspects and advantages of the present invention are described further in the following detailed description thereof.
Detailed Description of the Invention
The present invention provides a method for detoxifying selected pathogenic toxic antigens, e.g., B. pertussis toxin, for use in vaccine formulations, improved vaccine formulations containing the selected toxoid and the preparations containing the toxoided antigen.

It is reasonably expected that the method of the present invention is capable of toxoiding a number of toxic antigens from a variety of pathogenic microorganisms for which vaccines are desirable, e.g., tetanus toxin or diphtheria 5 toxin, among others. However, for ease of description and experimentation, the pertussis toxin from the pathogen Bordetella pertussis is employed herein to illustrate the efficacy of this toxoiding method.
10 Briefly described, the toxoided PT of this invention is produced by partially detoxifying the toxin using glutaraldehyde as a reagent and then reacting the PT with formaldehyde in the presence of amino acids.
15 According to this invention, extracts of PT are obtained from a fermentation broth .or culture of Bordetella pertussis. Various strains of B. pertussis for use in the methods of this invention are described and readily available in commercial collections, such as the American
20 Type Culture Collection, Rockville, Maryland. Any of these available strains may be used in the processes of the present invention, provided they are capable of producing the desired antigenic factor, PT, in adequate amounts in a liquid culture medium.
25
Examples of strains that may be employed in the present invention include, without limitation, B. pertussis phase I, B_. pertussis phase II, B.. pertussis phase I CS, 33. pertussis Tohama, B. pertussis strain 185- 30, B. pertussis strain 18-
30323, B. pertussis strain 134, B. pertussis strain 509, B_. pertussis strain Wellcome 28, and Office of Biologies B. pertussis strain 165. A preferred strain for use in the present invention is B. pertussis phase I, Tohama, which is available from the Institute of Fermentation, Osaka, Japan,
35 under accession number IFO-14073.

For use in the present invention the selected B. pertussis strain can be grown in a variety of ways known to one of skill in the art. Various cultivation methods are known which employ different cultivation steps, and liquid or solid media, depending on the quantity and origin or conservation method of the seed culture. However, any known method will suffice for use in the present invention which provides an inoculum of an conventionally acceptable size for large scale production.
A suitable medium for growth of a B. pertussis inoculum may be selected by one of skill in the art including, without limitation, Gengou medium [European patent No. 0 077 646; the media described in N. Andorn et al, Appl. Microbiol. Biotechnol. , 28:356- 360 (1988) and references cited therein; Verway medium [U. S. Patent 4,784,589]; synthetic medium B2 [P. Van Hemert, in Prog;. Indust. Microbiol., (Bull, M. J., ed) , vol. 13, p.151, Elsevier Sci., Amsterdam (1977) ] or described modifications thereof.
For growth of the B. pertussis culture, which is the starting material of the present invention, an inoculum is added to a suitable liquid medium and fermentation is conducted employing conventional fermentation methods and fermentor designs known in the art. Those of skill in the art will appreciate that different results may be obtained depending upon the selection of a particular combination of conventional fermentor design, fermentation medium, method and parameters. Preferred combinations for use in the present invention are those suitable for use in large- scale production. Examples of such combinations of methods, designs and media are exemplified in European patent application publication No.A 077,646; European patent application publication No.A 121,249; European patent application publication No.A 239,504; Andorn et al, Sato et al (1983), Sekura et al and Svoboda et al, all cited above. The methods described in European patent application publication No.A 121,249; Andorn et al, cited above, and

European patent application No.A 239,504 are most preferred.
In the practice of this invention, after completion of fermentation, the B. pertussis fermentation broth is maintained in a sterile condition to avoid denaturation and/or degradation of the desired PT factor. In a preferred embodiment of the invention the broth is cooled to 1-10°C and held at this temperature. The pH is adjusted to below 7.0. Preferably the pH is adjusted to a range of between about ρH6.0 and pH 6.4 with phosphoric or acetic acid. A preservative can optionally be added, e.g., sodium thimerosal to a final concentration of up to 0.2 g/1 or 2-phenoxy-ethanol up to a final concentration of between 0.5% to 1%, to the broth. If desired, a preservative may be also added to the buffer solutions used in the processes of this invention.
As an optional first step in the method of the invention, the fermentation broth can be passed over a filter to remove major particles and pellets therefrom, provided that contact is avoided with contamination risks from the environment. The resulting broth may be subjected to the following steps of the method. Alternatively, a more purified solution containing PT may be treated by the following steps. For ease of explanation, the method will refer to an «antigenic factor solution», which is defined as a preparation containing PT and optionally other B. pertussis antigenic factors, such as FHA. This preparation can include fermentation broth containing primarily PT, or a purified solution containing primarily other B. pertussis antigens with only contaminating amounts of PT.
According to the method of this invention the antigenic factor solution is diluted to a toxin concentration of approximately 0.02 to 2 mg/ml, preferably 0.1 to 0.25 mg/ml, in an aqueous medium buffered to approximately neutral pH,

i.e., pH 5 to about pH 9. Preferably the pH range is 7.5- 7.7. A desirable aqueous buffer for this dilution is phosphate buffered saline (PBS) . An exemplary buffer contains 50mM phosphate and 0.5 M NaCl, and is referred to herein as Buffer D.
After dilution, the solution may be optionally sterilized by filtration, e.g., through a 0.22 mem sterile membrane. The antigenic factor solution is treated with from 0.03 to 0.07% of a 25% aqueous solution of glutaraldehyde by weight. More preferably, a dilution containing 0.55% of the aqueous 25% glutaraldehyde solution is employed in this treatment step. For purposes of this step the 0.55% by weight glutaraldehyde is preferably present in the buffer D described above.
The glutaraldehyde solution is applied to the antigenic factor solution for approximately 1 to 4 hours. More preferably a range of 1 to 3 hours is employed in the glutaraldehyde treatment step, with a presently preferred time of 2 hours. The temperature of the glutaraldehyde treatment step is desirably ambient temperature, between approximately 20°C to 25°C. Optionally, shorter reaction times can be used in combination with higher than ambient temperatures, or longer times can be used with lower than ambient temperatures. Inactivation can also be obtained at different reaction temperatures and adequately modified contact times, for example, a temperature of 10°C may be used for 2 to 8 hours, more preferably for 4 hours. A temperature of 30°C may be employed for 30 minutes to 2 hours, more preferably 1 hour. Alternatively a temperature of 37°C may be used for between 15 minutes to 1 hour, more preferably 30 minutes. This glutaraldehyde treatment step may result in partial detoxification of the antigenic factor depending on the time of reaction and concentration of reagents. For example, glutaraldehyde treatment at the concentration described above for 2 hours at 20-25°C yields a reduction of 0.003% of the toxic activity. The other

treatment conditions may result in a greater reduction of toxic activity.
After this detoxification step, at least one selected amino acid is added to the partially detoxified antigenic factor in the solution. The amino acid is added to a final concentration of approximately 0.05 to 2% by weight. Preferred concentrations of the amino acid is 0.8% by weight.
The selected amino acids for use in this step may include tryptophan, glycine, lysine and derivatives thereof or other amino acids such as those present in protein hydrolyzates. Preferably the amino acids are tryptophan, lysine and glycine or derivatives thereof. The amino acids are preferably prepared in solution, e.g., in the Buffer D described above and may be added to the antigenic factor solution separately or as a mixture of two or more amino acids. In one presently preferred embodiment, three solutions are prepared in Buffer D which contain, respectively, 10% (w/v) Tween 80 solution, 33 ml of 57.4 mM N-acetyl-tryptophan and 11 ml of 2.2 M glycine. These three solutions are sterilized by filtration through a 0.22 mem sterile membrane.
The formalin is added to the antigenic factor and amino acid solution in a concentration of between 1 and 10% by weight, and more preferably 2-4% by weight. The formalin may also be prepared in Buffer D or a like buffer. The formalin is added to the antigenic factor/amino acid solution in approximately equivalent amounts over a period of between 3 to 10 days, more preferably 7 days. During the formalin treatment, the toxins are maintained at a temperature of between 37 to 45°C. In a preferred embodiment the toxins are maintained at between 39 to 41°C during this step.
Preferably the toxins are also agitated periodically during this period and kept under sterile conditions. At the end of the formalin/amino acid treatment step the detoxified B.

pertussis toxoid solution can be stored at low temperatures, preferably between 2-6°C overnight. Any aggregates formed during the detoxification process are then destroyed by subjecting the toxoid to ultrasonication. For example, the solution may be subjected to sonication at a frequency of about 16-80 KHz with a power of up to 1000 watts for a time of 1-30 seconds. Preferably the sonication involves a frequency of about 20 KHz. The range of power may more preferably be between 600-800 watts. The sonication time is preferably between 5 to 15 seconds. The resulting solution is filtered, preferably through a 50 mem screen.
As a final step in the detoxification method of this invention, the incubated product is dialyzed against PBS in a conventional manner to remove any excess reagents.
Changes of the dialysis buffer and the duration of dialysis are performed a sufficient number of times to provide that the residual formalin concentration is below 200 ppm. More preferably the formalin concentration is kept about 20 ppm. This concentration is sufficient to reduce the concentration of other agents used in the inactivation procedure to non- detectible or insignificant concentrations.
The resulting purified B. pertussis toxin or mixture of other B. pertussis antigenic factors containing PT toxoided by the method of this invention is characterized by complete and irreversible inactivation of toxicity. This stability against reversion to a toxic form is maintained even under conditions of storage in which the temperature is above room temperature, about 23°C. Such stability has been demonstrated in experimental tests for at least one week at 56°C and for at least four weeks at 37°C. Additionally, the toxoids of the invention are expected to remain stable for more than two years at cold storage temperatures of between 4 to 8°C. This resulting toxoid or antigenic factor may then

be employed as a component in B. pertussis antigen preparations which may be distributed for later preparation of vaccines or in vaccine formulations.
Therefore, this invention also provides vaccines which contain an immunoproteetive quantity of the toxoids or antigenic factors of the invention, i.e., enough of the toxoided PT or other antigenic factors are administered to elicit a protective antibody response against B_. pertussis infection without serious side effects. Such vaccines may be prepared by conventional techniques. For example, a vaccine for stimulating protection against B. pertussis infection in humans may contain stable toxoids and antigenic factors described above and a suitable conventional carrier. One or more of the toxoids or antigenic factors of this invention may be in an aqueous solution buffered at physiological pH for direct use. Alternatively, the toxoided antigens can be admixed or adsorbed with a conventional adjuvant, such as aluminum hydroxide or aluminum phosphate. Such a B. pertussis toxoid may also be combined with other immunogens to prepare combination or multi-functional vaccines capable of inducing protection against more than one pathogen. See, e.g., New Trends and Developments in Vaccines, eds. Voller et al, University Park Press, Baltimore, MD (1978) .
Such vaccines can be administered by an appropriate route, e.g., by the subcutaneous, intravenous or intramuscular routes. The amount of the selected toxoid of the invention present in each vaccine dose is selected by the attending physician with regard to consideration of the patient’s age, weight, sex, general physical condition and the like. The amount to induce an immunoproteetive response in the patient without significant adverse side effects may vary depending upon the immunogen employed and the optional presence of an adjuvant. Generally, it is expected that each dose will comprise 2 to 50 μ/gs of antigen, preferably 5 to 25 μ/gs

each of toxoid and antigenic factor. Initial doses may be optionally followed by repeated boosts, where desirable. The following examples illustrate the methods of preparing an exemplary toxoid of the invention, and assessments of its immunogenicity and resistance to reversion to toxicity during storage. Also illustrated is an exemplary vaccine preparation employing the toxoid of this invention.
Example 1 – Toxoiding Method
B. pertussis toxin was extracted and purified from fermentor growth cultures as described in European Patent Application Publication No. EP-A-0 352 250 which is incorporated herein by reference. One liter of the purified PT toxin was first treated at room temperature, e.g., 25°C, with 100 ml of a 0.55% (w/v) glutaraldehyde solution prepared in Buffer D. The solution is diluted to a final protein concentration of 0.2 mg/ml in Buffer D described above at neutral pH and is sterilized and filtered through a 0.22 mem sterile membrane. The glutaraldehyde treatment step is allowed to react for 2 hours. Then 4.4 ml of a 10% (w/v) Tween 80 solution, 33 ml of 57.4 mM N-Acetyl-Tryptophan and 11 ml of 2.2 M Glycine were added. These 3 solutions were prepared in the D buffer and sterilized by filtration through a 0.22 mem sterile membrane. Formalin, a 3.7% (w/v) solution in D buffer, was then added in 3 portions according to the following scheme: On the first day, 33 mis; on the second day, 33 mis; and on the third day 22 mis of formalin was added. The final formalin concentration was 0.26% (w/v). During the seven day formalin treatment, the PT toxin was maintained at 40°C ± 1°C under agitation and sterile conditions. At the end of the process, the detoxified PT bulk solution was stored overnight at 2-6°C before sonication. The solution was subjected to ultrasonication and the resulting antigen solution was filtered through a 50 mem screen.

Example 2 – Toxic Properties of the Vaccine Component
The toxoid preparation of Example 1 is compared with products prepared by toxoiding with glutaraldehyde alone, with formalin and amino acids only and with glutaraldehyde and formalin/amino acids as described herein to demonstrate the advantages of the products and methods of this invention.
A study of residual toxicity of the toxoids was conducted after each sample was stored.for 1 month at either 4°C or 37°C. The study included an examination of Chinese hamster ovary (CHO) cell morphology, in which cells exposed to active PT form clusters readily distinguishable from normally growing cells by one skill in the art. See, e.g., Gillenius et al, J. Biol. Stand., 11:61-66 (1985). The test is performed by mixing serial dilutions of the toxoid or antigenic factor being tested with a suspension of 2×104 CHO cells in 200 μl culture broth in microtitre plates, allowing the cells to settle and grow at 37°C for 2 days. At the end of the incubation, the clustering scores are recorded by microscopic examination. This test is sensitive to about 100 picograms of active toxin.
The results illustrated in TABLE 1 below show that treatment with formalin/amino acids alone yields complete inactivation, which however, is unstable and reverts to toxicity after 4 weeks at 37°C. Glutaraldehyde treatment alone yields incomplete, but stable inactivation. The process of the present invention, containing glutaraldehyde and formalin/amino acids treatment provides both complete and stable inactivation.

TABLE 1
Toxic Properties of Treated B. pertussis Toxin CHO Cells Morphology Test
Antigen Preparation CPU /meg
30 d – 4°C 30 d-37°C

* Corresponds to the detection limit of the assay. 1 CPU (cytopathie unit) is the smallest dose of antigen which induces alteration of morphology of all the cells. For native toxin, 1 CPU corresponds to a concentration of about 3 ng/ml.

The study also involved sL histamine sensitization test in mice with aluminum hydroxide adsorbed vaccine. Groups of 10 mice (Swiss OF1) are inoculated intravenously with one dose of vaccine, containing 6 μg of pertussis toxoid and 25 μg of treated FHA. After 4 days, the mice are challenged intraperitoneally with 1 mg histamine in buffered saline. Two hours after challenge, the mortality rate of each group is recorded. See, e.g., Munoz et al. Infect. Immunol., 3_3_:820-826 (1981). The histamine test is sensitive to about 30 ng active toxin/mouse.
The results of this assay are shown in TABLE 2 and demonstrate, like the CHO test, that the formalin/ amino acid treatment gave complete, but reversible inactivation upon incubation of the vaccine at 37°C for one month.
However, this test failed to detect toxicity or reversion to toxicity in both the glutaraldehyde and glutaraldehyde and formalin/amino acids treated preparations. This result is not contradictory to the CHO test results, because the histamine challenge test is less sensitive than the CHO test and does not detect the residual toxicity level in the glutaraldehyde treated samples.

TABLE 2
Toxic Properties of Adsorbed B. pertussis
Vaccine Preparations
Histamine Sensitization Test in Mice
Antigen Preparation Mortality Rate
30 d – 4°C 30 d – 37°C
(1) Formalin-amino 0/10 6/10 acids
(2) Glutaraldehyde 0/10 0/10
(3) Glutaraldehyde + 0/10 0/10 Formalin

Exa ple 3 – Antigenic Properties of the Vaccine Component
The toxoid preparations obtained by inactivation with formalin/amino acid treatment alone, glutaraldehyde treatment alone or the method of the present invention as described in Example 1 were tested in an enzyme immunoassay using a specific rabbit antibody directed against PT. This antibody was obtained by immunizing rabbits with toxoid inactivated by formalin/amino acids.
This antibody was conjugated to biotin to allow detection of bound antibody by a streptavidin:peroxidase reagent, by determination of absorbance at 490 nm.
The results are illustrated in TABLE 3. They show that native toxin is most efficiently recognized. Toxoid prepared by glutaraldehyde inactivation alone shows the lowest reactivity. Toxoids prepared by formalin/amino acid treatment or by the treatment of the method of this invention display an intermediate reactivity.
TABLE 3
Antigenic Properties of Toxoided PT Reaction
with Rabbit Anti-PT
Antigen Preparation D at 490 nm
Native toxin 0.74
Formalin/amino acids 0.39
Glutaraldehyde + formalin 0.26
Glutaraldehyde 0.12

Example 4 – Protective Efficacy of Toxoided PT in Mice.
Groups of 12 mice (Balb/c) were immunized by 2 μg of the toxoid preparations given twice at 7 days interval. 14 days after the second injection, they were challenged intranasally by a hypervirulent B. pertussis strain [ (18-323 Ac+) ; See, e.g., Brezin et al., FEMS Microbiol. Lett., 42.:75-80 (1987)). Mortalities were recorded 6 days after challenge.
The results illustrated in TABLE 4 below show that the method of the invention provides a B. pertussis toxoid with the best protective efficacy.
TABLE 4
Protective Efficacy of Toxoided PT in Mice
Antigen Preparation no of deaths
None 10 Formalin/amino acids 4
Glutaraldehyde . 6 Glutaraldehyde – formalin 2
Example 5 – Vaccine Preparation
To formulate vaccines, B. pertussis antigens must be devoid of toxic properties, while retaining satisfactory immunological properties. This objective is accomplished by toxoiding B. pertussis toxin and/or by similar treatment applied to other antigens, which generally contain

contaminating amounts of PT toxin. Treatment with glutaraldehyde as in U. S. Patent No. 4,675,321 results in incomplete inactivation. Treatment with formalin alone as in European Patent Application No. 121,249 results in a complete but partially reversible inactivation and conserved immunogenicity. However, application of the method of this invention, e.g., treatment of the PT containing solution with glutaraldehyde and formalin/amino acids as herein described results surprisingly in both complete inactivation and irreversible inactivation. The resulting solution also is characterized by conserved immunogenicity. Thus, the products and processes of the present invention are valuable for their contributions to the safety and immunogenicity of B_. pertussis vaccines containing these antigens.
Example 6 – Stability of the Vaccine Preparation
The vaccine preparation obtained by inactivation with the method of the present invention as described in Example 1 and the preparation procedure described in Example 5 were submitted to different heating treatments: one week at 56°C, 4 weeks at 37°C or kept for 1 year at 4-8°C. The vaccine samples were then assayed for active PT by the histamine sensitization assay in mice as described in Example 2. The results shown in Table 5 show the absence of reversion to toxicity after the above treatments.

TABLE 5
Toxic Properties of Adsorbed B. pertussis
Vaccine Preparation
Histamine sensitization test in mice
Preparation Mortality administered Treatment Dose rate
solvent 0/10
native PT 0.50 μg 10/10 0.17 μg 10/10 0.05 μg 6/10 vaccine none 25 μg 0/10 vaccine 7 days, 56°C 25 μg 0/10 vaccine 28 days, 37°C 25 μg 0/10 vaccine 1 year, 4-8°C 25 μg 0/10
Example 7 – Immunogenicity and stability upon long term storage at 4-8°C
Antigen preparations, formulated as in example 5, were stored at 4-8°C and assayed at various times for the histamine sensitizing activity of PT as described in example 2 and for the ED50 of the immune response of Swiss OFl mice to PT, i.e. the determination of the dose of inactivated PT needed to induce seroconversion of 50% of the mice. Similar tests were performed on adsorbed trivalent DTP vaccine, containing diphtheria toxoid, tetanus toxoid and the acellular pertussis vaccine components filamentous hemagglutinin and inactivated pertussis toxin prepared as described in example 1. The results (TABLE 6) show the absence of reversion and the absence of significant variations of the ED50.

Table 6: Immunogenicity and Stability Studies

(1) Inactivated PT, 25 μg.
(2) Trivalent DTP (diphtheria toxoid, tetanus toxoid, B. pertussis filamentous hemagglutinin (FHA) and inactivated PT, 25 μg) .
The method of the present invention may be applied to other antigens, such as diphtheria toxin, tetanus toxin and the like. Such modifications and alterations to the compositions and processes of the present invention are intended to be encompassed in the scope of the claims appended hereto.

Claims (14)

Claims

A method for the detoxification of a toxic antigen from a partially or extensively purified preparation containing said antigen from a pathogenic microorganism comprising treating said preparation with glutaraldehyde to partially detoxify said antigen, and reacting the partially detoxified antigen with formalin in the presence of selected amino acids.

The method according to claim 1 wherein said antigen is pertussis toxin.

3. The method according to claim 1 wherein said amino acids are selected from the group consisting of tryptophan, glycine, lysine and derivatives thereof.

4. The method according to claim 1 wherein said glutaraldehyde treatment comprises treating an aqueous solution containing said antigen at a concentration of between 0.02 to 2 mg/ml with from 0.03 to 0.07% of 25% aqueous glutaraldehyde solution by weight.

5. The method according to claim 4 wherein said formalin and amino acid treatment comprises adding to said glutaraldehyde treated antigen solution between about 0.05 to 2% by weight of at least one selected amino acid and between 1 to 10% by weight formalin, maintaining said solution at a temperature of between 37 to 45°C.

6. The method according to claim 5 further comprising optionally subjecting the solution to ultrasonication to remove aggregates formed during detoxification.

7. The method according to claim 5 comprising dialyzing the solution to remove excess reagent, wherein the residual formalin concentration is always below 200ppm in said solution.
5

8. A detoxified B. pertussis toxin capable of retaining its stability against reversion to toxicity under temperatures above about 23°C.

10 9. A composition of B. pertussis antigenic factors containing a detoxified B_. pertussis toxin capable of retaining its stability against reversion to toxicity under temperatures above room temperature.

1510. The toxin according to claim 8 characterized by stability for more than one month upon exposure to a temperature of up to 37°C.

11. A pathogenic toxic antigen detoxified by the method of 20 claim 1.

12. A 33. pertussis vaccine comprising an immunogenic amount of a pertussis toxin of claim 8, characterized by stability at temperatures of up to 37°C.
25

13. The vaccine according to claim 12 further comprising an immunogenic amount of a detoxified toxin of a second pathogenic organism, wherein said vaccine is multi-functional.
30

14. A vaccine against a selected pathogen comprising an immunogenic amount of a detoxified antigen of claim 11.

AU72110/91A
1990-02-12
1991-02-07
Novel vaccine and method therefor

Expired

AU646019B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US47909890A

1990-02-12
1990-02-12

US479098

1990-02-12

Publications (2)

Publication Number
Publication Date

AU7211091A
true

AU7211091A
(en)

1991-09-03

AU646019B2

AU646019B2
(en)

1994-02-03

Family
ID=23902647
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU72110/91A
Expired

AU646019B2
(en)

1990-02-12
1991-02-07
Novel vaccine and method therefor

Country Status (17)

Country
Link

EP
(1)

EP0515415B1
(en)

JP
(1)

JP3035712B2
(en)

KR
(1)

KR100202052B1
(en)

AT
(1)

ATE129159T1
(en)

AU
(1)

AU646019B2
(en)

CA
(1)

CA2075711C
(en)

CY
(1)

CY1935A
(en)

DE
(1)

DE69113991T2
(en)

DK
(1)

DK0515415T3
(en)

ES
(1)

ES2080941T3
(en)

GR
(1)

GR3018440T3
(en)

HK
(1)

HK1004524A1
(en)

IE
(1)

IE70672B1
(en)

NZ
(1)

NZ237069A
(en)

PT
(1)

PT96723B
(en)

WO
(1)

WO1991012020A1
(en)

ZA
(1)

ZA91947B
(en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

EP2156845A1
(en)

1992-05-23
2010-02-24
GlaxoSmithKline Biologicals SA
Combined vaccines comprising hepatitis B surface antigen and other antigens

GB9216351D0
(en)

1992-07-31
1992-09-16
Wellcome Found
Vaccine production

AU5441199A
(en)

1998-09-01
2000-03-21
Elan Corporation, Plc
Oral vaccine compositions

AU769539B2
(en)

1999-01-29
2004-01-29
Zoetis Services Llc
Adjuvants for use in vaccines

GB0313916D0
(en)

2003-06-16
2003-07-23
Glaxosmithkline Biolog Sa
Vaccine composition

CN104093416B
(en)

2012-02-01
2016-10-19
葛兰素史密丝克莱恩生物有限公司
Fermentation process

US20140037680A1
(en)

2012-08-06
2014-02-06
Glaxosmithkline Biologicals, S.A.
Novel method

WO2014024026A1
(en)

2012-08-06
2014-02-13
Glaxosmithkline Biologicals S.A.
Method for eliciting in infants an immune response against rsv and b. pertussis

EA030749B1
(en)

2013-03-08
2018-09-28
Янссен Вэксинс Энд Превеншн Б.В.
Acellular pertussis vaccine

US9849066B2
(en)

2013-04-24
2017-12-26
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients

BR112016002354A2
(en)

2013-08-05
2017-09-12
Glaxosmithkline Biologicals Sa

immunogenic composition, methods to protect a baby against infection or disease and to evoke an immune response, vaccination regimen, and

Family Cites Families (5)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4075321A
(en)

1973-05-04
1978-02-21
Agence Nationale De Valorisation De La Recherche (Anvar)
Vaccines, the process for preparing the same and the applications thereof

JPS5750925A
(en)

1980-09-12
1982-03-25
Takeda Chem Ind Ltd
Preparation of pertussis toxoid

GB8601279D0
(en)

1986-01-20
1986-02-26
Public Health Lab Service
Purification of pertussis antigens

US4888169A
(en)

1986-10-14
1989-12-19
Norden Laboratories, Inc.
Bordetella Bronchiseptica vaccine

WO1990009444A1
(en)

1989-02-10
1990-08-23
Genesit Oy
A method for producing pertussis toxin subunits

1991

1991-02-07
EP
EP91903336A
patent/EP0515415B1/en
not_active
Expired – Lifetime

1991-02-07
AU
AU72110/91A
patent/AU646019B2/en
not_active
Expired

1991-02-07
CA
CA002075711A
patent/CA2075711C/en
not_active
Expired – Lifetime

1991-02-07
ES
ES91903336T
patent/ES2080941T3/en
not_active
Expired – Lifetime

1991-02-07
WO
PCT/EP1991/000257
patent/WO1991012020A1/en
active
IP Right Grant

1991-02-07
DE
DE69113991T
patent/DE69113991T2/en
not_active
Expired – Lifetime

1991-02-07
AT
AT91903336T
patent/ATE129159T1/en
not_active
IP Right Cessation

1991-02-07
DK
DK91903336.5T
patent/DK0515415T3/en
active

1991-02-07
CY
CY193591A
patent/CY1935A/en
unknown

1991-02-07
JP
JP03503734A
patent/JP3035712B2/en
not_active
Expired – Lifetime

1991-02-08
PT
PT96723A
patent/PT96723B/en
not_active
IP Right Cessation

1991-02-08
IE
IE42491A
patent/IE70672B1/en
not_active
IP Right Cessation

1991-02-08
ZA
ZA91947A
patent/ZA91947B/en
unknown

1991-02-11
NZ
NZ237069A
patent/NZ237069A/en
unknown

1992

1992-08-11
KR
KR1019920701931A
patent/KR100202052B1/en
not_active
IP Right Cessation

1995

1995-12-15
GR
GR950403570T
patent/GR3018440T3/en
unknown

1998

1998-04-28
HK
HK98103622A
patent/HK1004524A1/en
not_active
IP Right Cessation

Also Published As

Publication number
Publication date

IE70672B1
(en)

1996-12-11

GR3018440T3
(en)

1996-03-31

CA2075711C
(en)

2000-11-07

DK0515415T3
(en)

1995-11-27

CY1935A
(en)

1991-02-07

DE69113991D1
(en)

1995-11-23

EP0515415A1
(en)

1992-12-02

NZ237069A
(en)

1993-07-27

JP3035712B2
(en)

2000-04-24

AU646019B2
(en)

1994-02-03

ES2080941T3
(en)

1996-02-16

ZA91947B
(en)

1992-01-29

ATE129159T1
(en)

1995-11-15

IE910424A1
(en)

1991-08-14

JPH05503936A
(en)

1993-06-24

DE69113991T2
(en)

1996-03-21

WO1991012020A1
(en)

1991-08-22

HK1004524A1
(en)

1998-11-27

PT96723B
(en)

1998-07-31

CA2075711A1
(en)

1991-08-13

EP0515415B1
(en)

1995-10-18

KR920703099A
(en)

1992-12-17

KR100202052B1
(en)

1999-06-15

PT96723A
(en)

1991-10-31

Información de contacto